fluticasone propionate + tiotropium

Fluticasone propionate + tiotropium is a combination of two inhaled medications used primarily in the management of chronic obstructive pulmonary disease (COPD). Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by inhibiting multiple types of inflammatory cells and decreasing the production of cytokines and other mediators. Tiotropium is a long-acting antimuscarinic bronchodilator (LAMA) that works by blocking muscarinic M3 receptors in airway smooth muscle, leading to sustained bronchodilation. The combination aims to improve lung function, reduce symptoms, decrease exacerbations, and enhance quality of life for patients with COPD. Clinical studies have shown that adding fluticasone propionate to tiotropium therapy results in greater improvements in lung function and health-related quality of life compared to tiotropium alone[1][2][9]. This combination may be used as part of triple therapy with other agents such as long-acting beta agonists.